Fig. 4.

Antagomir-148a treatment during the effector response of an acute immune reaction does not reduce memory T cell populations or circulating antigen-specific IgG titers. (A) Schematic diagram showing the experimental procedure for eliciting a vaccine-like induced immune response and subsequent antagomir treatment during the effector phase after boosting with NP-CGG and IFA. (B, C) Cell numbers of splenic memory T cell populations in immunized mice that were treated with antagomir-148a or antagomir-Scr as shown in Figure 4A. (D) Blood sera of mice that were treated as shown in (A) were collected on day 28 and NP-CGG-specific antibody titers were determined by ELISA. Data in (B) and (C) are pooled from two independent experiments with n = 11 antagomir-Scr-treated mice and n = 12 antagomir-148a-treated mice. Data in (D) are from one experiment with n = 7 for both antagomir-148a- and antagomir-Scr-treated mice.